Pomalidomide for Multiple Myeloma – National Cancer Institute.
Multiple myeloma | |
---|---|
Classification and external resources | |
![]() Micrograph of a plasmacytoma, the histologiccorrelate of multiple myeloma. H&E stain
|
|
ICD–10 | C90.0 |
ICD–9 | 203.0 |
ICD-O: | M9732/3 |
OMIM | 254500 |
DiseasesDB | 8628 |
MedlinePlus | 000583 |
eMedicine | med/1521 |
MeSH | D009101 |
![]() |
|
Systematic (IUPAC) name | |
---|---|
4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | |
Clinical data | |
Trade names | Imnovid, Pomalyst |
Licence data | EMA:Link, US FDA:link |
Pregnancy cat. | X (US) |
Legal status | POM (UK) ℞-only (US) |
Routes | Oral |
Pharmacokinetic data | |
Protein binding | 12–44% |
Metabolism | Hepatic (mostly CYP1A2 andCYP3A4 mediated; some minor contributions by CYP2C19 andCYP2D6) |
Half-life | 7.5 hours |
Excretion | Urine (73%), faeces (15%) |
Identifiers | |
CAS number | 19171-19-8 ![]() |
ATC code | L04AX06 |
PubChem | CID 134780 |
ChemSpider | 118785 ![]() |
UNII | D2UX06XLB5 ![]() |
ChEMBL | CHEMBL43452 ![]() |
Chemical data | |
Formula | C13H11N3O4 |
Mol. mass | 273.24 g/mol |
Related articles